1) we need NEW validated leads
2) we need clinical progress of VP-001
Stepping back as a third party observer - a fair read by the market on us = underwhelmed; slow, no surprise progress updates, milestones communicated via presentations still pending/delayed
as a shareholder - maybe I suffer from confirmation bias, but I believe 1st quarter 2022 is where we’ll hit some concrete milestones and deliver:
- 2 NEW validated leads which we will be confirmed to be taken to clinical via an aggressive parallel timeframe
- VP-001 announced milestones hit
- PYC extends platform to be a CNS pre-clinical player
Ann: Change in substantial holding, page-22
-
- There are more pages in this discussion • 39 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
14.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $676.5M | |||
| Open | High | Low | Value | Volume |
| 14.0¢ | 14.5¢ | 13.5¢ | $687.7K | 4.887M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 87494 | 14.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 15.0¢ | 2187900 | 13 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| PYC (ASX) Chart |